Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial

Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial

Abstract Background Diphereline is a Gonadotropin-Releasing Hormone agonist commonly used in patients with breast cancer. This study aimed to compare the efficacy and safety of one-month and three-month Microrelin injections produced by Homa Pharmed Company with three-month Diphereline injections ma...

Full description

Bibliographic Details
Main Authors: Safa Najafi, Maryam Ansari, Zahra Omidi, Asiie Olfatbakhsh, Shiva Moghadam, Esmat-o-Sadat Hashemi, Niki Najafi, Shahpar Haghighat
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Cancer
Subjects:
Breast cancer
Diphereline
Microrelin
Gonadotropin-releasing hormone agonist
Iran
Online Access:https://doi.org/10.1186/s12885-023-11614-7

Internet

https://doi.org/10.1186/s12885-023-11614-7

Similar Items